- Home
- SUPN vs SRRK Comparison
SUPN vs SRRK Comparison
Compare SUPN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- SRRK
- Stock Information
- Founded
- SUPN 2005
- SRRK 2012
- Country
- SUPN United States
- SRRK United States
- Employees
- SUPN N/A
- SRRK N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUPN Health Care
- SRRK Health Care
- Exchange
- SUPN Nasdaq
- SRRK Nasdaq
- Market Cap
- SUPN 2.6B
- SRRK 3.0B
- IPO Year
- SUPN 2012
- SRRK 2018
- Fundamental
- Price
- SUPN $44.80
- SRRK $31.95
- Analyst Decision
- SUPN Buy
- SRRK Strong Buy
- Analyst Count
- SUPN 2
- SRRK 8
- Target Price
- SUPN $43.00
- SRRK $44.29
- AVG Volume (30 Days)
- SUPN 654.2K
- SRRK 1.9M
- Earning Date
- SUPN 11-03-2025
- SRRK 11-11-2025
- Dividend Yield
- SUPN N/A
- SRRK N/A
- EPS Growth
- SUPN 1411.53
- SRRK N/A
- EPS
- SUPN 1.14
- SRRK N/A
- Revenue
- SUPN $665,125,000.00
- SRRK N/A
- Revenue This Year
- SUPN $4.84
- SRRK N/A
- Revenue Next Year
- SUPN $17.69
- SRRK $1,996.18
- P/E Ratio
- SUPN $38.93
- SRRK N/A
- Revenue Growth
- SUPN 5.55
- SRRK N/A
- 52 Week Low
- SUPN $29.16
- SRRK $6.76
- 52 Week High
- SUPN $46.79
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- SUPN 58.16
- SRRK 45.44
- Support Level
- SUPN $43.44
- SRRK $30.07
- Resistance Level
- SUPN $46.72
- SRRK $34.27
- Average True Range (ATR)
- SUPN 1.08
- SRRK 1.67
- MACD
- SUPN -0.48
- SRRK 0.09
- Stochastic Oscillator
- SUPN 40.60
- SRRK 37.19
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.